Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04927065 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
A Phase 2 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 2
- Development phase
- 5,161
- Enrollment target
NCT04927065 is a Phase 2 study that has completed, run by ModernaTX. The registered enrollment target is 5,161 participants.
The verdict
NCT04927065, a Phase 2 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5,161 participants
- Enrollment target
Study Summary
This is a study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, and mRNA-1273.231 administered as booster doses.
Interventions
- BIOLOGICAL mRNA-1273
- BIOLOGICAL mRNA-1273.211
- BIOLOGICAL mRNA-1273.617.2
- BIOLOGICAL mRNA-1273.213
- BIOLOGICAL mRNA-1273.529
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,161 participants |
| Start Date | 2021-05-28 |
| Est. Completion | 2023-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04927065
The ClinicalTrials.gov registry entry for NCT04927065 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5,161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which mRNA-1273 is the first listed.
NCT04927065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04927065 about?
NCT04927065 is a clinical study titled "A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants". This is a study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, and mRNA-1273.231 administered as booster doses.
What is the current status of trial NCT04927065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5,161 participants. The study started on 2021-05-28. Estimated completion is 2023-11-17.
What interventions are being tested in trial NCT04927065?
The interventions under investigation include: mRNA-1273 (BIOLOGICAL), mRNA-1273.211 (BIOLOGICAL), mRNA-1273.617.2 (BIOLOGICAL), mRNA-1273.213 (BIOLOGICAL), mRNA-1273.529 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04927065?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.